SlideShare a Scribd company logo
1 of 116
Download to read offline
Pharmaceutics Lecture
2002 - Date
Computing
and
pharmaceutical numeracy
Dr. L.T.M. Muungo, PhD
Review of Mathematical Concepts for
Pharmaceutics
▪Proper, Improper Fractions & Mixed Numbers
▪To add or Subtract Fractions
▪Multiplication of Fractions
▪Decimals
1. Proper, Improper Fractions and Mixed Numbers
➢Proper fraction: numerator is less than denominator; value is less than 1.
Example: 1/2
➢Improper fraction: numerator is greater than denominator; value is greater than 1.
Example: 4/3.
➢Or numerator denominator; value 1.
Example: 5/5
➢Mixed number: whole number a fraction; value is greater than 1.
Example: 1(1/2)
➢Complex fraction: numerator and/or denominator are composed of a fraction, decimal,
or mixed number; value is less than, greater than, or = 1.
Example: (1/2) / (1/50)
➢Any nonzero number divided by itself 1.
Example: (3/3) = 1
➢To reduce a fraction to lowest terms, divide both terms by the largest nonzero whole
number that will divide both the numerator and denominator evenly. Value remains the
same.
Example: 1/6 = (6/2) / (10/2) = 3/5
➢To enlarge a fraction, multiply both terms by the same nonzero number. Value remains
the same.
Example: 1/12 = (1x2) / (12x2) = 2/24
➢To convert a mixed number to an improper fraction, multiply the whole number by the
denominator and add the numerator; use original denominator in the fractional part.
Example: 1(1/3) = 4/3
➢To convert an improper fraction to a mixed number, divide the numerator by the
denominator.
➢Express any remainder as a proper fraction reduced to lowest terms.
Example: 21/9 = 2(3/9) = 2(1/3)
➢When numerators are equal, the fraction with the smaller denominator is greater.
Example: 1/2 is greater than 1/3
➢When denominators are equal, the fraction with the larger numerator is greater.
Example: 2/3 is greater than 1/3
2. To add or subtract fractions:
➢ Convert to equivalent fractions with least common denominators.
➢ Add or subtract the numerators; place that value in the numerator.
➢Use the least common denominator as the denominator.
➢ Convert the answer to a mixed number and/or reduce to lowest terms.
3. Multiplication of Fractions
➢When multiplying a fraction by a nonzero whole number, the same rule applies as for
multiplying fractions.
➢First convert the whole number to a fraction with a denominator of 1; the value of the
➢number remains the same.
Example (2/3) x (4/1)
➢To multiply mixed numbers, first convert them to improper fractions, and then multiply.
Example 31/2 x 41/3 = 7/2 x 13/3
➢To divide mixed numbers, first convert them to improper fractions.
Example[1(1/2)] / (3/4) = (3/2) / (3/4) = (3/2) x (4/3) = (1/1) x (2/1) = 2
➢To multiply fractions, cancel terms, multiply numerators, and multiply denominators.
➢ To divide fractions, invert the divisor, cancel terms, and multiply.
➢ Convert results to a mixed number and/or reduce to lowest terms.
4. Decimals
➢In a decimal number, whole number values are to the left of the decimal point, and
fractional values are to the right.
➢Zeros added to a decimal fraction before the decimal point of a decimal number less
than 1 or at the end of the decimal fraction do not change the value.
Example: .5 = 0.5 = 0.50. However, using the leading zero is the only
acceptable notation (such as, 0.5).
➢In a decimal number, zeros added before or after the decimal point may change the
value.
Example: 1.5 ≠ 1.05 and 1.5 ≠ 10.5.
➢To avoid overlooking the decimal point in a decimal fraction, always place a zero to the
left of the decimal point.
Example: .5 ← Avoid writing a decimal fraction this way; it could be mistaken
for the whole number 5.
Example: 0.5 ←. This is the required method of writing a decimal fraction with a
value less than 1
➢The number of places in a decimal fraction indicates the power of 10.
Examples:
0.5 = five tenths
0.05 = five hundredths
0.005 = five thousandths
Compare decimals by aligning decimal points and adding zeros.
Example:
Compare 0.5, 0.05, and 0.005.
0.500 = five hundred thousandths (greatest)
0.050 = fifty thousandths
0.005 = five thousandths (least)
To convert a fraction to a decimal, divide the numerator by the denominator.
To convert a decimal to a fraction, express the decimal number as a whole number in
the numerator and the denominator as the correct power of 10. Reduce the fraction to
lowest terms.
Example:
0.04 = 4 (numerator is a whole number)
100 (denominator is 1 followed by two zeros)
= 4/100
= 1/25
To multiply decimals, place the decimal point in the product to the left as many decimal
places as there are in the two decimals multiplied.
Example:
0.25 x 0.2 = 0.050 = 0.05 (Zeros at the end of the decimal are unnecessary).
To divide decimals, move the decimal point in the divisor and dividend the number of
decimal places that will make the divisor a whole number and align it in the quotient.
Example: 24 / 1.2
To multiply or divide decimals by a power of 10, move the decimal point to the right (to
multiply) or to the left (to divide) the number of decimal places as there are zeros in the
power of 10.
Examples:
5.06 x10 = 5.0.6 = 50.6
2.1 /100 = .02.1 = 0.021
When rounding decimals, add 1 to the place value considered if the next decimal place
is 5 or greater.
Examples:
Rounded to hundredths: 3.054 = 3.05; 0.566 = 0.57.
Rounded to tenths: 3.05 = 3.1; 0.54 = 0.5
Any Questions or Additions
Basic Fundamental Characteristics
of
Pharmaceutical Dosage Forms
▪Liquid Dosage Forms
▪Solid Dosage Forms
▪Semisolid Dosage Forms
▪Moulded Solid Dosage Forms
▪Sterile Dosage Forms
▪Weights and Measures
Weights and Measures
Any Questions or Additions
Pharmaceutical Calculations
Reducing & Enlarging Formulas
Percentage Preparations
Ratio Strength
Dilution & Concentration
Dilution and Concentration
STUDY QUESTIONS
FOR
PHARMACEUTICAL NUMERACY
Study Questions
• Define the following terms:
• [Proper fraction, improper fraction, multiplication, Decimal, numerator, denominator, dosage form,
solution, syrup, suspension, emulsion, tablet, capsule, powder, ointment, cream, gel, paste, suppository,
pessary, parenteral, ophthalmic, oral, intravenous, intramuscular, subcutaneous, buccal, sublingual, rectal,
inhalation, topical, transdermal, balance, measuring cylinder, beaker, mortar, dropper, metric, millimetre,
micrometre, nanometre, ingredient, ratio strength, dilution, concentration, stock solution, alligation, etc]
• Respond to the following questions:
➢ State and explain the main some of the mathematical concepts used in the process of quantitative
and qualitative determinations in pharmaceutical procedures
➢ State and explain the basic fundamental characteristics of pharmaceutical dosage forms considered
in the process of quantitative and qualitative determinations in pharmaceutical procedures
➢ Explain the differences between metric and common systems of pharmaceutical measuring process
➢ Illustrate the process of reducing and enlarging formulas in the pharmaceutical calculations
➢ Illustrate the process of dilution and concentration of the formulas in the pharmaceutical
calculations
➢ Illustrate the process of alligation of the formulas in the pharmaceutical calculations
Group work discussional questions:
1. A liquid medicine is supplied in a concentration of 20 mg/5 mL. A patient requires 40 mg
orally three times daily for 5 days, then 20 mg three times daily for 5 days, then 20 mg
twice daily for 5 days and then 20 mg once daily for 5 days. Calculate the total volume of
liquid medicine that is precisely to be dispensed
2. You are required to make 350 g of a paste that contains 15% w/w zinc oxide. What is the
amount of zinc oxide required?
3. A 1 in 10 000 solution of potassium permanganate contains how much of the quantity from
the given ration
4. How much of the volumes of an adrenaline 1 in 100 solution would be given by
intramuscular injection to a 2-year-old child for treatment of anaphylaxis if the dose were
120 micrograms stat?
5. How much of copper sulphate is required to make 400 mL of an aqueous stock solution,
such that, when the stock solution is diluted 50 times with water, a final solution of 0.1%
w/v copper sulphate is produced?
6. How much of Magnesium sulphate is required to make 1000 mL of an aqueous stock
solution, such that, when the stock solution is diluted 100 times with water, a final solution
of 0.5% w/v copper sulphate is produced?
7. A child requires a single oral daily dose of 7.0 mg/kg body weight of drug A. The child’s
weight is 8.0 kg. How much of the oral daily doses of drug A is received by this child?
8. A patient in one of the residential homes to which you supply medication is going on
holiday and needs her prescriptions made up for the 5 days that she will be away. If she
usually takes ranitidine 150 mg twice daily and atenolol 50 mg in the morning, calculate
the appropriate combinations of Zantac syrup (75 mg ranitidine/5 mL) and Tenormin syrup
(25 mg atenolol/5 mL) that would be supplied?
9. Potassium permanganate solution 1 in 8000 is prepared from a stock of 10 times this
strength. How much potassium permanganate will be needed to make sufficient stock
solution if a patient uses 200 mL of the diluted solution each day for 20 days?
10. What volume of phenytoin suspension 30 mg/5 mL is required to be added to a suitable
diluent to obtain 150 mL phenytoin suspension 20 mg/5 mL?
11. Given a 20% w/v solution of chlorhexidine gluconate, what volume is required to make
400 mL of a 2% w/v solution?
12. You are presented with a prescription for allopurinol tablets 100 mg at a dose of 300 mg
each day for 14 days, reducing to 200 mg for a further 7 days. How many packs of 28
tablets should you supply?
13. An injection solution contains 0.5% w/v of active ingredient. How much of the active
ingredient is needed to prepare 500 L of solution?
14. A patient taking 10.0 mL Erythroped suspension (250 mg/5 mL) qid will receive how much
erythromycin each day?
15. Calculate the number of days a 150 mL bottle of nitrazepam 2.5 mg/5 mL suspension will
last a patient prescribed nitrazepam 5 mg at bedtime for insomnia.
16. Calculate the number of tablets required to fulfil the following prescription:
▪ Prednisolone 5 mg e/c tablets
▪ Take 25 mg daily for 4 days, then reduce by 5 mg every 4 days until the course is
finished (total course: 20 days)
17. The number of drops per minute required if 720 mL of 5% w/v glucose is to be given
intravenously to a patient over a 12-hour period. It is known that 20 drops = 1 mL.
18. You receive a prescription for phenindione tablets 50 mg with the following
instructions: ‘200 mg on day 1, 100 mg on day 2 and then 50 mg daily thereafter’.
Mitte: 56 days’ supply. Which of the following is the correct quantity to supply?
19. An ointment contains 1% w/w calamine. Which of the following is the amount of
calamine powder that should be added to 200 g of the ointment to produce a 4% w/w
calamine ointment?
20. A patient weighing 30 kg requires a single oral daily dose of 9 mg/kg of drug B. This
drug is available only as a suspension of 15 mg/5 mL. How much suspension would
you supply? Which of the following is the volume of a 6% w/v solution that is required
to give a single dose of 12 mg?
21. Which of the following is the concentration of a solution prepared by dissolving 400
mg potassium permanganate in water and making up to a final volume of 4.0 L.
22. The volume of amoxicillin syrup 125 mg/5 mL required by a child prescribed 250 mg
amoxicillin orally three times daily for 5 days.
23. The volume of a 5% w/v solution required to give a dose of 40 mg.
24. The volume required to give a 15 mg dose of haloperidol from a 2 mL ampoule
containing 10 mg haloperidol/mL.
25. You mix together 50 g of 0.5% w/w hydrocortisone cream and 25 g of 2% w/w
sulphur cream (the creams are compatible). What is the final concentration of each of
the two drugs?
26 A patient weighing 50 kg requires a single oral daily dose of 9 mg/kg of drug Y. This
drug is available only as a suspension of 150 mg/5 mL. How much suspension would
it be most appropriate to supply to provide a single dose?
27. You have in your pharmacy a cream containing 0.5% w/w hydrocortisone. You have
been requested to use this cream as a base and to add in sufficient calamine such
that the final concentration of calamine in the new cream will be 10.0% w/w. What is
the concentration of hydrocortisone in the new cream?
28. A stock solution of drug G is available at 10%w/v. You need to dilute this with Syrup,
BP in order to supply a patient with a solution containing 5 mg/mL of drug G.
Assuming no volume displacement effects, what is your formula for the preparation
of 100 mL of the final solution
29. A patient is on a continuous intravenous drip of drug B. He needs to be dosed at a
rate of 25 mg/h. The drip is set to administer 10 drops of fluid/h, with 4 drops
equaling 1 mL in volume. Which of the following is the concentration of drug B in the
intravenous fluid?
30. The amount of phytomenadione contained in a 0.2 mL ampoule of 10 mg/mL
solution.
31. The weight of chlorhexidine contained in 2 mL of a 1 in 10 000 solution.
32. The weight of ethambutol contained in 0.4 mL of 250 micrograms/mL solution.
33. What is the correct volume of a 5% w/v solution required to supply 150 mg of the
active ingredient?
34. What is the amount of fluorescein sodium in 300 mL of a 2.8% w/v aqueous solution.
35. What is the amount of 5-aminolevulinic acid hydrochloride in 25 g of a 20% w/w
cream.
36. How much active substance is required to manufacture a batch of granules for a
compressed tablet with a batch size of 420 kg, to produce tablets with a mean weight
of 700 mg and an active substance content of 600 mg?
37. Given that the relative molecular mass (RMM) of sodium chloride is 58.5 g/mol, what
amounts of sodium chloride powder would be required to prepare 300 mL of a
solution containing 50 mmol/L?
38. A tablet labelled to contain 350 mg active ingredient has acceptable limits of 90–
110% of that amount. What are the corresponding figures in milligrams to the stated
percentage range ?
39. How much of the amount of sodium ions does 50 mL sodium chloride solution 0.9%
w/v intravenous infusion contain if there are 150 mmol each of Na+ and Cl–/L of
NaCl 0.9% w/v IV infusion.
40. The amount of sodium chloride required to make 500 mL of a 0.1 mol/L solution
(relative atomic mass [RAM]: sodium = 23; chlorine = 35.5.)
41. The amount of lymeycline contained in five Tetralysal 300 tablets. Each tablet
contains 408 mg lymecycline equivalent to 300 mg tetracycline.
42. What is the number of moles of 5-aminolevulinic acid hydrochloride in 50 mL of a 1
mol/L solution?
Reference:
1. Dosage Calculations: A Ratio-Proportion Approach, Gloria D. Pickar, EdD, RN
2007, 2nd Edition
2. Pharmaceutical and Clinical Calculations, Mansoor A.Khan. and Indra K. Reddy,
2000, 2nd Ed.

More Related Content

Similar to 1-1-Computing and Pharmaceutical Numeracy.pdf

Week 1 Roman Numerals and Fractions
Week 1 Roman Numerals and FractionsWeek 1 Roman Numerals and Fractions
Week 1 Roman Numerals and Fractionskwcrowther
 
Drug calculation
Drug calculationDrug calculation
Drug calculationmarenam
 
12446567 basic-computations-2-iv-ivf
12446567 basic-computations-2-iv-ivf12446567 basic-computations-2-iv-ivf
12446567 basic-computations-2-iv-ivfNgaire Taylor
 
Fundamentals of measurement and calculation
Fundamentals of measurement and calculationFundamentals of measurement and calculation
Fundamentals of measurement and calculationAfkar432
 
Introduction to mathematics in nursing 2012
Introduction to mathematics in nursing 2012Introduction to mathematics in nursing 2012
Introduction to mathematics in nursing 2012RWJ2012
 
Drug calculation tutorial_091407
Drug calculation tutorial_091407Drug calculation tutorial_091407
Drug calculation tutorial_091407olayski
 
Mastering Dosing Calculations
Mastering Dosing CalculationsMastering Dosing Calculations
Mastering Dosing CalculationsLynn Bahena
 
Percentages
PercentagesPercentages
Percentageswindleh
 
4_2021_07_16!07_37_45_PM.pdf
4_2021_07_16!07_37_45_PM.pdf4_2021_07_16!07_37_45_PM.pdf
4_2021_07_16!07_37_45_PM.pdfShahnawazHasan4
 
Good practice for drug calculations
Good practice for drug calculationsGood practice for drug calculations
Good practice for drug calculationsMEEQAT HOSPITAL
 
Mod3 rwjf introduction to mathematics for nursing v2a - revised 06262013
Mod3   rwjf introduction to mathematics for nursing v2a - revised 06262013Mod3   rwjf introduction to mathematics for nursing v2a - revised 06262013
Mod3 rwjf introduction to mathematics for nursing v2a - revised 06262013University of Miami
 
Intro 120919143739-phpapp02
Intro 120919143739-phpapp02Intro 120919143739-phpapp02
Intro 120919143739-phpapp02zahranurainiyyah
 
1 percent,ratio,conc,dilution
1 percent,ratio,conc,dilution1 percent,ratio,conc,dilution
1 percent,ratio,conc,dilutionrashakhalaf1
 
Week 2 Decimal Numbers and Percents
Week 2 Decimal Numbers and PercentsWeek 2 Decimal Numbers and Percents
Week 2 Decimal Numbers and Percentskwcrowther
 
HSNS565 Medication Mastery
HSNS565 Medication MasteryHSNS565 Medication Mastery
HSNS565 Medication MasteryPushpa Nepal
 
CONVERSIONS-ch 6edited
CONVERSIONS-ch 6editedCONVERSIONS-ch 6edited
CONVERSIONS-ch 6editedKaren Hatten
 

Similar to 1-1-Computing and Pharmaceutical Numeracy.pdf (20)

Week 1 Roman Numerals and Fractions
Week 1 Roman Numerals and FractionsWeek 1 Roman Numerals and Fractions
Week 1 Roman Numerals and Fractions
 
Drug calculation
Drug calculationDrug calculation
Drug calculation
 
Fractions
FractionsFractions
Fractions
 
12446567 basic-computations-2-iv-ivf
12446567 basic-computations-2-iv-ivf12446567 basic-computations-2-iv-ivf
12446567 basic-computations-2-iv-ivf
 
Fundamentals of measurement and calculation
Fundamentals of measurement and calculationFundamentals of measurement and calculation
Fundamentals of measurement and calculation
 
Introduction to mathematics in nursing 2012
Introduction to mathematics in nursing 2012Introduction to mathematics in nursing 2012
Introduction to mathematics in nursing 2012
 
Drug calculation tutorial_091407
Drug calculation tutorial_091407Drug calculation tutorial_091407
Drug calculation tutorial_091407
 
Pharmacy calculations
Pharmacy calculationsPharmacy calculations
Pharmacy calculations
 
Mastering Dosing Calculations
Mastering Dosing CalculationsMastering Dosing Calculations
Mastering Dosing Calculations
 
Percentages
PercentagesPercentages
Percentages
 
4_2021_07_16!07_37_45_PM.pdf
4_2021_07_16!07_37_45_PM.pdf4_2021_07_16!07_37_45_PM.pdf
4_2021_07_16!07_37_45_PM.pdf
 
Good practice for drug calculations
Good practice for drug calculationsGood practice for drug calculations
Good practice for drug calculations
 
Mod3 rwjf introduction to mathematics for nursing v2a - revised 06262013
Mod3   rwjf introduction to mathematics for nursing v2a - revised 06262013Mod3   rwjf introduction to mathematics for nursing v2a - revised 06262013
Mod3 rwjf introduction to mathematics for nursing v2a - revised 06262013
 
Intro 120919143739-phpapp02
Intro 120919143739-phpapp02Intro 120919143739-phpapp02
Intro 120919143739-phpapp02
 
1 percent,ratio,conc,dilution
1 percent,ratio,conc,dilution1 percent,ratio,conc,dilution
1 percent,ratio,conc,dilution
 
Week 2 Decimal Numbers and Percents
Week 2 Decimal Numbers and PercentsWeek 2 Decimal Numbers and Percents
Week 2 Decimal Numbers and Percents
 
HSNS565 Medication Mastery
HSNS565 Medication MasteryHSNS565 Medication Mastery
HSNS565 Medication Mastery
 
CONVERSIONS-ch 6edited
CONVERSIONS-ch 6editedCONVERSIONS-ch 6edited
CONVERSIONS-ch 6edited
 
Calcul-Part.ppt
Calcul-Part.pptCalcul-Part.ppt
Calcul-Part.ppt
 
Intro
IntroIntro
Intro
 

More from MuungoLungwani

1-2-PhysicalState of Matter.pdf
1-2-PhysicalState of Matter.pdf1-2-PhysicalState of Matter.pdf
1-2-PhysicalState of Matter.pdfMuungoLungwani
 
2-4-PhaseEquilibriumGeneric.pdf
2-4-PhaseEquilibriumGeneric.pdf2-4-PhaseEquilibriumGeneric.pdf
2-4-PhaseEquilibriumGeneric.pdfMuungoLungwani
 
1-3-Physical Properties of Pharmaceutical-Related Materials.pdf
1-3-Physical Properties of Pharmaceutical-Related Materials.pdf1-3-Physical Properties of Pharmaceutical-Related Materials.pdf
1-3-Physical Properties of Pharmaceutical-Related Materials.pdfMuungoLungwani
 
2-5-PhaseEquilibriaPharmacy.pdf
2-5-PhaseEquilibriaPharmacy.pdf2-5-PhaseEquilibriaPharmacy.pdf
2-5-PhaseEquilibriaPharmacy.pdfMuungoLungwani
 
PMY 6110_1-4-Pharmaceutical Care Plan.pdf
PMY 6110_1-4-Pharmaceutical Care Plan.pdfPMY 6110_1-4-Pharmaceutical Care Plan.pdf
PMY 6110_1-4-Pharmaceutical Care Plan.pdfMuungoLungwani
 
PMY 6110_1-5-Illustration of Bedridden Patient Management.pdf
PMY 6110_1-5-Illustration of Bedridden Patient Management.pdfPMY 6110_1-5-Illustration of Bedridden Patient Management.pdf
PMY 6110_1-5-Illustration of Bedridden Patient Management.pdfMuungoLungwani
 
PMY 6110_1-1-General In - Copy.pdf
PMY 6110_1-1-General In - Copy.pdfPMY 6110_1-1-General In - Copy.pdf
PMY 6110_1-1-General In - Copy.pdfMuungoLungwani
 
PMY 6110_1-7-Principles of Nutraceutical Care.pdf
PMY 6110_1-7-Principles of Nutraceutical Care.pdfPMY 6110_1-7-Principles of Nutraceutical Care.pdf
PMY 6110_1-7-Principles of Nutraceutical Care.pdfMuungoLungwani
 
PMY 6110_1-6-Pharmaceutical Care Evaluation.pdf
PMY 6110_1-6-Pharmaceutical Care Evaluation.pdfPMY 6110_1-6-Pharmaceutical Care Evaluation.pdf
PMY 6110_1-6-Pharmaceutical Care Evaluation.pdfMuungoLungwani
 
PMY 6110_1-1-General Information on Clinical Pharmacy.pdf
PMY 6110_1-1-General Information on Clinical Pharmacy.pdfPMY 6110_1-1-General Information on Clinical Pharmacy.pdf
PMY 6110_1-1-General Information on Clinical Pharmacy.pdfMuungoLungwani
 
PMY 6110_1-3-Therapeuti - Copy.pdf
PMY 6110_1-3-Therapeuti - Copy.pdfPMY 6110_1-3-Therapeuti - Copy.pdf
PMY 6110_1-3-Therapeuti - Copy.pdfMuungoLungwani
 
PMY 6110_2-2-Gastrointestinal Diseases.pdf
PMY 6110_2-2-Gastrointestinal Diseases.pdfPMY 6110_2-2-Gastrointestinal Diseases.pdf
PMY 6110_2-2-Gastrointestinal Diseases.pdfMuungoLungwani
 
PMY 6110_1-4-Pharmaceutical Care.pdf
PMY 6110_1-4-Pharmaceutical Care.pdfPMY 6110_1-4-Pharmaceutical Care.pdf
PMY 6110_1-4-Pharmaceutical Care.pdfMuungoLungwani
 
PMY 6110_1-3-Therapeutical Process Assessment.pdf
PMY 6110_1-3-Therapeutical Process Assessment.pdfPMY 6110_1-3-Therapeutical Process Assessment.pdf
PMY 6110_1-3-Therapeutical Process Assessment.pdfMuungoLungwani
 
PMY 6110_1-2-Principles of Pharmaceutical Care 1.pdf
PMY 6110_1-2-Principles of Pharmaceutical Care 1.pdfPMY 6110_1-2-Principles of Pharmaceutical Care 1.pdf
PMY 6110_1-2-Principles of Pharmaceutical Care 1.pdfMuungoLungwani
 
PMY 6110_1-2-Principles - Copy.pdf
PMY 6110_1-2-Principles - Copy.pdfPMY 6110_1-2-Principles - Copy.pdf
PMY 6110_1-2-Principles - Copy.pdfMuungoLungwani
 
0-Curriculum - 2010-Date MCPharmUNZA - FinalCopy.pdf
0-Curriculum - 2010-Date MCPharmUNZA - FinalCopy.pdf0-Curriculum - 2010-Date MCPharmUNZA - FinalCopy.pdf
0-Curriculum - 2010-Date MCPharmUNZA - FinalCopy.pdfMuungoLungwani
 
PMY 6120_1-1-Preformulation Characteristics of Pharmaceutical Product Systems...
PMY 6120_1-1-Preformulation Characteristics of Pharmaceutical Product Systems...PMY 6120_1-1-Preformulation Characteristics of Pharmaceutical Product Systems...
PMY 6120_1-1-Preformulation Characteristics of Pharmaceutical Product Systems...MuungoLungwani
 
PMY 6120_1-2-Pharmaceutical Formulation Systems_Compound and Dispensing Proce...
PMY 6120_1-2-Pharmaceutical Formulation Systems_Compound and Dispensing Proce...PMY 6120_1-2-Pharmaceutical Formulation Systems_Compound and Dispensing Proce...
PMY 6120_1-2-Pharmaceutical Formulation Systems_Compound and Dispensing Proce...MuungoLungwani
 
1-Course MaterialOutline PMY 5021 - 2017.pdf
1-Course MaterialOutline PMY 5021  - 2017.pdf1-Course MaterialOutline PMY 5021  - 2017.pdf
1-Course MaterialOutline PMY 5021 - 2017.pdfMuungoLungwani
 

More from MuungoLungwani (20)

1-2-PhysicalState of Matter.pdf
1-2-PhysicalState of Matter.pdf1-2-PhysicalState of Matter.pdf
1-2-PhysicalState of Matter.pdf
 
2-4-PhaseEquilibriumGeneric.pdf
2-4-PhaseEquilibriumGeneric.pdf2-4-PhaseEquilibriumGeneric.pdf
2-4-PhaseEquilibriumGeneric.pdf
 
1-3-Physical Properties of Pharmaceutical-Related Materials.pdf
1-3-Physical Properties of Pharmaceutical-Related Materials.pdf1-3-Physical Properties of Pharmaceutical-Related Materials.pdf
1-3-Physical Properties of Pharmaceutical-Related Materials.pdf
 
2-5-PhaseEquilibriaPharmacy.pdf
2-5-PhaseEquilibriaPharmacy.pdf2-5-PhaseEquilibriaPharmacy.pdf
2-5-PhaseEquilibriaPharmacy.pdf
 
PMY 6110_1-4-Pharmaceutical Care Plan.pdf
PMY 6110_1-4-Pharmaceutical Care Plan.pdfPMY 6110_1-4-Pharmaceutical Care Plan.pdf
PMY 6110_1-4-Pharmaceutical Care Plan.pdf
 
PMY 6110_1-5-Illustration of Bedridden Patient Management.pdf
PMY 6110_1-5-Illustration of Bedridden Patient Management.pdfPMY 6110_1-5-Illustration of Bedridden Patient Management.pdf
PMY 6110_1-5-Illustration of Bedridden Patient Management.pdf
 
PMY 6110_1-1-General In - Copy.pdf
PMY 6110_1-1-General In - Copy.pdfPMY 6110_1-1-General In - Copy.pdf
PMY 6110_1-1-General In - Copy.pdf
 
PMY 6110_1-7-Principles of Nutraceutical Care.pdf
PMY 6110_1-7-Principles of Nutraceutical Care.pdfPMY 6110_1-7-Principles of Nutraceutical Care.pdf
PMY 6110_1-7-Principles of Nutraceutical Care.pdf
 
PMY 6110_1-6-Pharmaceutical Care Evaluation.pdf
PMY 6110_1-6-Pharmaceutical Care Evaluation.pdfPMY 6110_1-6-Pharmaceutical Care Evaluation.pdf
PMY 6110_1-6-Pharmaceutical Care Evaluation.pdf
 
PMY 6110_1-1-General Information on Clinical Pharmacy.pdf
PMY 6110_1-1-General Information on Clinical Pharmacy.pdfPMY 6110_1-1-General Information on Clinical Pharmacy.pdf
PMY 6110_1-1-General Information on Clinical Pharmacy.pdf
 
PMY 6110_1-3-Therapeuti - Copy.pdf
PMY 6110_1-3-Therapeuti - Copy.pdfPMY 6110_1-3-Therapeuti - Copy.pdf
PMY 6110_1-3-Therapeuti - Copy.pdf
 
PMY 6110_2-2-Gastrointestinal Diseases.pdf
PMY 6110_2-2-Gastrointestinal Diseases.pdfPMY 6110_2-2-Gastrointestinal Diseases.pdf
PMY 6110_2-2-Gastrointestinal Diseases.pdf
 
PMY 6110_1-4-Pharmaceutical Care.pdf
PMY 6110_1-4-Pharmaceutical Care.pdfPMY 6110_1-4-Pharmaceutical Care.pdf
PMY 6110_1-4-Pharmaceutical Care.pdf
 
PMY 6110_1-3-Therapeutical Process Assessment.pdf
PMY 6110_1-3-Therapeutical Process Assessment.pdfPMY 6110_1-3-Therapeutical Process Assessment.pdf
PMY 6110_1-3-Therapeutical Process Assessment.pdf
 
PMY 6110_1-2-Principles of Pharmaceutical Care 1.pdf
PMY 6110_1-2-Principles of Pharmaceutical Care 1.pdfPMY 6110_1-2-Principles of Pharmaceutical Care 1.pdf
PMY 6110_1-2-Principles of Pharmaceutical Care 1.pdf
 
PMY 6110_1-2-Principles - Copy.pdf
PMY 6110_1-2-Principles - Copy.pdfPMY 6110_1-2-Principles - Copy.pdf
PMY 6110_1-2-Principles - Copy.pdf
 
0-Curriculum - 2010-Date MCPharmUNZA - FinalCopy.pdf
0-Curriculum - 2010-Date MCPharmUNZA - FinalCopy.pdf0-Curriculum - 2010-Date MCPharmUNZA - FinalCopy.pdf
0-Curriculum - 2010-Date MCPharmUNZA - FinalCopy.pdf
 
PMY 6120_1-1-Preformulation Characteristics of Pharmaceutical Product Systems...
PMY 6120_1-1-Preformulation Characteristics of Pharmaceutical Product Systems...PMY 6120_1-1-Preformulation Characteristics of Pharmaceutical Product Systems...
PMY 6120_1-1-Preformulation Characteristics of Pharmaceutical Product Systems...
 
PMY 6120_1-2-Pharmaceutical Formulation Systems_Compound and Dispensing Proce...
PMY 6120_1-2-Pharmaceutical Formulation Systems_Compound and Dispensing Proce...PMY 6120_1-2-Pharmaceutical Formulation Systems_Compound and Dispensing Proce...
PMY 6120_1-2-Pharmaceutical Formulation Systems_Compound and Dispensing Proce...
 
1-Course MaterialOutline PMY 5021 - 2017.pdf
1-Course MaterialOutline PMY 5021  - 2017.pdf1-Course MaterialOutline PMY 5021  - 2017.pdf
1-Course MaterialOutline PMY 5021 - 2017.pdf
 

Recently uploaded

DBX First Quarter 2024 Investor Presentation
DBX First Quarter 2024 Investor PresentationDBX First Quarter 2024 Investor Presentation
DBX First Quarter 2024 Investor PresentationDropbox
 
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...apidays
 
[BuildWithAI] Introduction to Gemini.pdf
[BuildWithAI] Introduction to Gemini.pdf[BuildWithAI] Introduction to Gemini.pdf
[BuildWithAI] Introduction to Gemini.pdfSandro Moreira
 
FWD Group - Insurer Innovation Award 2024
FWD Group - Insurer Innovation Award 2024FWD Group - Insurer Innovation Award 2024
FWD Group - Insurer Innovation Award 2024The Digital Insurer
 
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data DiscoveryTrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data DiscoveryTrustArc
 
CNIC Information System with Pakdata Cf In Pakistan
CNIC Information System with Pakdata Cf In PakistanCNIC Information System with Pakdata Cf In Pakistan
CNIC Information System with Pakdata Cf In Pakistandanishmna97
 
presentation ICT roal in 21st century education
presentation ICT roal in 21st century educationpresentation ICT roal in 21st century education
presentation ICT roal in 21st century educationjfdjdjcjdnsjd
 
Architecting Cloud Native Applications
Architecting Cloud Native ApplicationsArchitecting Cloud Native Applications
Architecting Cloud Native ApplicationsWSO2
 
Cyberprint. Dark Pink Apt Group [EN].pdf
Cyberprint. Dark Pink Apt Group [EN].pdfCyberprint. Dark Pink Apt Group [EN].pdf
Cyberprint. Dark Pink Apt Group [EN].pdfOverkill Security
 
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024Victor Rentea
 
Polkadot JAM Slides - Token2049 - By Dr. Gavin Wood
Polkadot JAM Slides - Token2049 - By Dr. Gavin WoodPolkadot JAM Slides - Token2049 - By Dr. Gavin Wood
Polkadot JAM Slides - Token2049 - By Dr. Gavin WoodJuan lago vázquez
 
Exploring the Future Potential of AI-Enabled Smartphone Processors
Exploring the Future Potential of AI-Enabled Smartphone ProcessorsExploring the Future Potential of AI-Enabled Smartphone Processors
Exploring the Future Potential of AI-Enabled Smartphone Processorsdebabhi2
 
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
"I see eyes in my soup": How Delivery Hero implemented the safety system for ..."I see eyes in my soup": How Delivery Hero implemented the safety system for ...
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...Zilliz
 
Why Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire businessWhy Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire businesspanagenda
 
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...Orbitshub
 
AWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of TerraformAWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of TerraformAndrey Devyatkin
 
AXA XL - Insurer Innovation Award Americas 2024
AXA XL - Insurer Innovation Award Americas 2024AXA XL - Insurer Innovation Award Americas 2024
AXA XL - Insurer Innovation Award Americas 2024The Digital Insurer
 
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, AdobeApidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobeapidays
 
Apidays New York 2024 - The value of a flexible API Management solution for O...
Apidays New York 2024 - The value of a flexible API Management solution for O...Apidays New York 2024 - The value of a flexible API Management solution for O...
Apidays New York 2024 - The value of a flexible API Management solution for O...apidays
 

Recently uploaded (20)

DBX First Quarter 2024 Investor Presentation
DBX First Quarter 2024 Investor PresentationDBX First Quarter 2024 Investor Presentation
DBX First Quarter 2024 Investor Presentation
 
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
 
[BuildWithAI] Introduction to Gemini.pdf
[BuildWithAI] Introduction to Gemini.pdf[BuildWithAI] Introduction to Gemini.pdf
[BuildWithAI] Introduction to Gemini.pdf
 
FWD Group - Insurer Innovation Award 2024
FWD Group - Insurer Innovation Award 2024FWD Group - Insurer Innovation Award 2024
FWD Group - Insurer Innovation Award 2024
 
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data DiscoveryTrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
TrustArc Webinar - Unlock the Power of AI-Driven Data Discovery
 
CNIC Information System with Pakdata Cf In Pakistan
CNIC Information System with Pakdata Cf In PakistanCNIC Information System with Pakdata Cf In Pakistan
CNIC Information System with Pakdata Cf In Pakistan
 
presentation ICT roal in 21st century education
presentation ICT roal in 21st century educationpresentation ICT roal in 21st century education
presentation ICT roal in 21st century education
 
Architecting Cloud Native Applications
Architecting Cloud Native ApplicationsArchitecting Cloud Native Applications
Architecting Cloud Native Applications
 
Cyberprint. Dark Pink Apt Group [EN].pdf
Cyberprint. Dark Pink Apt Group [EN].pdfCyberprint. Dark Pink Apt Group [EN].pdf
Cyberprint. Dark Pink Apt Group [EN].pdf
 
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
Modular Monolith - a Practical Alternative to Microservices @ Devoxx UK 2024
 
Polkadot JAM Slides - Token2049 - By Dr. Gavin Wood
Polkadot JAM Slides - Token2049 - By Dr. Gavin WoodPolkadot JAM Slides - Token2049 - By Dr. Gavin Wood
Polkadot JAM Slides - Token2049 - By Dr. Gavin Wood
 
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
 
Exploring the Future Potential of AI-Enabled Smartphone Processors
Exploring the Future Potential of AI-Enabled Smartphone ProcessorsExploring the Future Potential of AI-Enabled Smartphone Processors
Exploring the Future Potential of AI-Enabled Smartphone Processors
 
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
"I see eyes in my soup": How Delivery Hero implemented the safety system for ..."I see eyes in my soup": How Delivery Hero implemented the safety system for ...
"I see eyes in my soup": How Delivery Hero implemented the safety system for ...
 
Why Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire businessWhy Teams call analytics are critical to your entire business
Why Teams call analytics are critical to your entire business
 
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
 
AWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of TerraformAWS Community Day CPH - Three problems of Terraform
AWS Community Day CPH - Three problems of Terraform
 
AXA XL - Insurer Innovation Award Americas 2024
AXA XL - Insurer Innovation Award Americas 2024AXA XL - Insurer Innovation Award Americas 2024
AXA XL - Insurer Innovation Award Americas 2024
 
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, AdobeApidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
 
Apidays New York 2024 - The value of a flexible API Management solution for O...
Apidays New York 2024 - The value of a flexible API Management solution for O...Apidays New York 2024 - The value of a flexible API Management solution for O...
Apidays New York 2024 - The value of a flexible API Management solution for O...
 

1-1-Computing and Pharmaceutical Numeracy.pdf

  • 1. Pharmaceutics Lecture 2002 - Date Computing and pharmaceutical numeracy Dr. L.T.M. Muungo, PhD
  • 2. Review of Mathematical Concepts for Pharmaceutics ▪Proper, Improper Fractions & Mixed Numbers ▪To add or Subtract Fractions ▪Multiplication of Fractions ▪Decimals
  • 3. 1. Proper, Improper Fractions and Mixed Numbers ➢Proper fraction: numerator is less than denominator; value is less than 1. Example: 1/2 ➢Improper fraction: numerator is greater than denominator; value is greater than 1. Example: 4/3. ➢Or numerator denominator; value 1. Example: 5/5 ➢Mixed number: whole number a fraction; value is greater than 1. Example: 1(1/2) ➢Complex fraction: numerator and/or denominator are composed of a fraction, decimal, or mixed number; value is less than, greater than, or = 1. Example: (1/2) / (1/50) ➢Any nonzero number divided by itself 1. Example: (3/3) = 1 ➢To reduce a fraction to lowest terms, divide both terms by the largest nonzero whole number that will divide both the numerator and denominator evenly. Value remains the same. Example: 1/6 = (6/2) / (10/2) = 3/5
  • 4. ➢To enlarge a fraction, multiply both terms by the same nonzero number. Value remains the same. Example: 1/12 = (1x2) / (12x2) = 2/24 ➢To convert a mixed number to an improper fraction, multiply the whole number by the denominator and add the numerator; use original denominator in the fractional part. Example: 1(1/3) = 4/3 ➢To convert an improper fraction to a mixed number, divide the numerator by the denominator. ➢Express any remainder as a proper fraction reduced to lowest terms. Example: 21/9 = 2(3/9) = 2(1/3) ➢When numerators are equal, the fraction with the smaller denominator is greater. Example: 1/2 is greater than 1/3 ➢When denominators are equal, the fraction with the larger numerator is greater. Example: 2/3 is greater than 1/3 2. To add or subtract fractions: ➢ Convert to equivalent fractions with least common denominators. ➢ Add or subtract the numerators; place that value in the numerator. ➢Use the least common denominator as the denominator. ➢ Convert the answer to a mixed number and/or reduce to lowest terms.
  • 5. 3. Multiplication of Fractions ➢When multiplying a fraction by a nonzero whole number, the same rule applies as for multiplying fractions. ➢First convert the whole number to a fraction with a denominator of 1; the value of the ➢number remains the same. Example (2/3) x (4/1) ➢To multiply mixed numbers, first convert them to improper fractions, and then multiply. Example 31/2 x 41/3 = 7/2 x 13/3 ➢To divide mixed numbers, first convert them to improper fractions. Example[1(1/2)] / (3/4) = (3/2) / (3/4) = (3/2) x (4/3) = (1/1) x (2/1) = 2 ➢To multiply fractions, cancel terms, multiply numerators, and multiply denominators. ➢ To divide fractions, invert the divisor, cancel terms, and multiply. ➢ Convert results to a mixed number and/or reduce to lowest terms.
  • 6. 4. Decimals ➢In a decimal number, whole number values are to the left of the decimal point, and fractional values are to the right. ➢Zeros added to a decimal fraction before the decimal point of a decimal number less than 1 or at the end of the decimal fraction do not change the value. Example: .5 = 0.5 = 0.50. However, using the leading zero is the only acceptable notation (such as, 0.5). ➢In a decimal number, zeros added before or after the decimal point may change the value. Example: 1.5 ≠ 1.05 and 1.5 ≠ 10.5. ➢To avoid overlooking the decimal point in a decimal fraction, always place a zero to the left of the decimal point. Example: .5 ← Avoid writing a decimal fraction this way; it could be mistaken for the whole number 5. Example: 0.5 ←. This is the required method of writing a decimal fraction with a value less than 1 ➢The number of places in a decimal fraction indicates the power of 10. Examples: 0.5 = five tenths 0.05 = five hundredths 0.005 = five thousandths
  • 7. Compare decimals by aligning decimal points and adding zeros. Example: Compare 0.5, 0.05, and 0.005. 0.500 = five hundred thousandths (greatest) 0.050 = fifty thousandths 0.005 = five thousandths (least) To convert a fraction to a decimal, divide the numerator by the denominator. To convert a decimal to a fraction, express the decimal number as a whole number in the numerator and the denominator as the correct power of 10. Reduce the fraction to lowest terms. Example: 0.04 = 4 (numerator is a whole number) 100 (denominator is 1 followed by two zeros) = 4/100 = 1/25
  • 8. To multiply decimals, place the decimal point in the product to the left as many decimal places as there are in the two decimals multiplied. Example: 0.25 x 0.2 = 0.050 = 0.05 (Zeros at the end of the decimal are unnecessary). To divide decimals, move the decimal point in the divisor and dividend the number of decimal places that will make the divisor a whole number and align it in the quotient. Example: 24 / 1.2 To multiply or divide decimals by a power of 10, move the decimal point to the right (to multiply) or to the left (to divide) the number of decimal places as there are zeros in the power of 10. Examples: 5.06 x10 = 5.0.6 = 50.6 2.1 /100 = .02.1 = 0.021 When rounding decimals, add 1 to the place value considered if the next decimal place is 5 or greater. Examples: Rounded to hundredths: 3.054 = 3.05; 0.566 = 0.57. Rounded to tenths: 3.05 = 3.1; 0.54 = 0.5
  • 9. Any Questions or Additions
  • 10.
  • 11. Basic Fundamental Characteristics of Pharmaceutical Dosage Forms ▪Liquid Dosage Forms ▪Solid Dosage Forms ▪Semisolid Dosage Forms ▪Moulded Solid Dosage Forms ▪Sterile Dosage Forms ▪Weights and Measures
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46.
  • 47.
  • 48.
  • 49.
  • 50.
  • 51.
  • 52.
  • 53.
  • 54.
  • 55.
  • 56.
  • 57. Any Questions or Additions
  • 58. Pharmaceutical Calculations Reducing & Enlarging Formulas Percentage Preparations Ratio Strength Dilution & Concentration
  • 59.
  • 60.
  • 61.
  • 62.
  • 63.
  • 64.
  • 65.
  • 66.
  • 67.
  • 68.
  • 70.
  • 71.
  • 72.
  • 73.
  • 74.
  • 75.
  • 76.
  • 77.
  • 78.
  • 79.
  • 80.
  • 81.
  • 82.
  • 83.
  • 84.
  • 85.
  • 86.
  • 87.
  • 88.
  • 89.
  • 90.
  • 91.
  • 92.
  • 93.
  • 94.
  • 95.
  • 96.
  • 97.
  • 98.
  • 99.
  • 100.
  • 101.
  • 102.
  • 103.
  • 104.
  • 105.
  • 106.
  • 107.
  • 108.
  • 110. Study Questions • Define the following terms: • [Proper fraction, improper fraction, multiplication, Decimal, numerator, denominator, dosage form, solution, syrup, suspension, emulsion, tablet, capsule, powder, ointment, cream, gel, paste, suppository, pessary, parenteral, ophthalmic, oral, intravenous, intramuscular, subcutaneous, buccal, sublingual, rectal, inhalation, topical, transdermal, balance, measuring cylinder, beaker, mortar, dropper, metric, millimetre, micrometre, nanometre, ingredient, ratio strength, dilution, concentration, stock solution, alligation, etc] • Respond to the following questions: ➢ State and explain the main some of the mathematical concepts used in the process of quantitative and qualitative determinations in pharmaceutical procedures ➢ State and explain the basic fundamental characteristics of pharmaceutical dosage forms considered in the process of quantitative and qualitative determinations in pharmaceutical procedures ➢ Explain the differences between metric and common systems of pharmaceutical measuring process ➢ Illustrate the process of reducing and enlarging formulas in the pharmaceutical calculations ➢ Illustrate the process of dilution and concentration of the formulas in the pharmaceutical calculations ➢ Illustrate the process of alligation of the formulas in the pharmaceutical calculations
  • 111. Group work discussional questions: 1. A liquid medicine is supplied in a concentration of 20 mg/5 mL. A patient requires 40 mg orally three times daily for 5 days, then 20 mg three times daily for 5 days, then 20 mg twice daily for 5 days and then 20 mg once daily for 5 days. Calculate the total volume of liquid medicine that is precisely to be dispensed 2. You are required to make 350 g of a paste that contains 15% w/w zinc oxide. What is the amount of zinc oxide required? 3. A 1 in 10 000 solution of potassium permanganate contains how much of the quantity from the given ration 4. How much of the volumes of an adrenaline 1 in 100 solution would be given by intramuscular injection to a 2-year-old child for treatment of anaphylaxis if the dose were 120 micrograms stat? 5. How much of copper sulphate is required to make 400 mL of an aqueous stock solution, such that, when the stock solution is diluted 50 times with water, a final solution of 0.1% w/v copper sulphate is produced? 6. How much of Magnesium sulphate is required to make 1000 mL of an aqueous stock solution, such that, when the stock solution is diluted 100 times with water, a final solution of 0.5% w/v copper sulphate is produced? 7. A child requires a single oral daily dose of 7.0 mg/kg body weight of drug A. The child’s weight is 8.0 kg. How much of the oral daily doses of drug A is received by this child? 8. A patient in one of the residential homes to which you supply medication is going on holiday and needs her prescriptions made up for the 5 days that she will be away. If she usually takes ranitidine 150 mg twice daily and atenolol 50 mg in the morning, calculate the appropriate combinations of Zantac syrup (75 mg ranitidine/5 mL) and Tenormin syrup (25 mg atenolol/5 mL) that would be supplied?
  • 112. 9. Potassium permanganate solution 1 in 8000 is prepared from a stock of 10 times this strength. How much potassium permanganate will be needed to make sufficient stock solution if a patient uses 200 mL of the diluted solution each day for 20 days? 10. What volume of phenytoin suspension 30 mg/5 mL is required to be added to a suitable diluent to obtain 150 mL phenytoin suspension 20 mg/5 mL? 11. Given a 20% w/v solution of chlorhexidine gluconate, what volume is required to make 400 mL of a 2% w/v solution? 12. You are presented with a prescription for allopurinol tablets 100 mg at a dose of 300 mg each day for 14 days, reducing to 200 mg for a further 7 days. How many packs of 28 tablets should you supply? 13. An injection solution contains 0.5% w/v of active ingredient. How much of the active ingredient is needed to prepare 500 L of solution? 14. A patient taking 10.0 mL Erythroped suspension (250 mg/5 mL) qid will receive how much erythromycin each day? 15. Calculate the number of days a 150 mL bottle of nitrazepam 2.5 mg/5 mL suspension will last a patient prescribed nitrazepam 5 mg at bedtime for insomnia. 16. Calculate the number of tablets required to fulfil the following prescription: ▪ Prednisolone 5 mg e/c tablets ▪ Take 25 mg daily for 4 days, then reduce by 5 mg every 4 days until the course is finished (total course: 20 days) 17. The number of drops per minute required if 720 mL of 5% w/v glucose is to be given intravenously to a patient over a 12-hour period. It is known that 20 drops = 1 mL.
  • 113. 18. You receive a prescription for phenindione tablets 50 mg with the following instructions: ‘200 mg on day 1, 100 mg on day 2 and then 50 mg daily thereafter’. Mitte: 56 days’ supply. Which of the following is the correct quantity to supply? 19. An ointment contains 1% w/w calamine. Which of the following is the amount of calamine powder that should be added to 200 g of the ointment to produce a 4% w/w calamine ointment? 20. A patient weighing 30 kg requires a single oral daily dose of 9 mg/kg of drug B. This drug is available only as a suspension of 15 mg/5 mL. How much suspension would you supply? Which of the following is the volume of a 6% w/v solution that is required to give a single dose of 12 mg? 21. Which of the following is the concentration of a solution prepared by dissolving 400 mg potassium permanganate in water and making up to a final volume of 4.0 L. 22. The volume of amoxicillin syrup 125 mg/5 mL required by a child prescribed 250 mg amoxicillin orally three times daily for 5 days. 23. The volume of a 5% w/v solution required to give a dose of 40 mg. 24. The volume required to give a 15 mg dose of haloperidol from a 2 mL ampoule containing 10 mg haloperidol/mL. 25. You mix together 50 g of 0.5% w/w hydrocortisone cream and 25 g of 2% w/w sulphur cream (the creams are compatible). What is the final concentration of each of the two drugs? 26 A patient weighing 50 kg requires a single oral daily dose of 9 mg/kg of drug Y. This drug is available only as a suspension of 150 mg/5 mL. How much suspension would it be most appropriate to supply to provide a single dose?
  • 114. 27. You have in your pharmacy a cream containing 0.5% w/w hydrocortisone. You have been requested to use this cream as a base and to add in sufficient calamine such that the final concentration of calamine in the new cream will be 10.0% w/w. What is the concentration of hydrocortisone in the new cream? 28. A stock solution of drug G is available at 10%w/v. You need to dilute this with Syrup, BP in order to supply a patient with a solution containing 5 mg/mL of drug G. Assuming no volume displacement effects, what is your formula for the preparation of 100 mL of the final solution 29. A patient is on a continuous intravenous drip of drug B. He needs to be dosed at a rate of 25 mg/h. The drip is set to administer 10 drops of fluid/h, with 4 drops equaling 1 mL in volume. Which of the following is the concentration of drug B in the intravenous fluid? 30. The amount of phytomenadione contained in a 0.2 mL ampoule of 10 mg/mL solution. 31. The weight of chlorhexidine contained in 2 mL of a 1 in 10 000 solution. 32. The weight of ethambutol contained in 0.4 mL of 250 micrograms/mL solution. 33. What is the correct volume of a 5% w/v solution required to supply 150 mg of the active ingredient? 34. What is the amount of fluorescein sodium in 300 mL of a 2.8% w/v aqueous solution. 35. What is the amount of 5-aminolevulinic acid hydrochloride in 25 g of a 20% w/w cream.
  • 115. 36. How much active substance is required to manufacture a batch of granules for a compressed tablet with a batch size of 420 kg, to produce tablets with a mean weight of 700 mg and an active substance content of 600 mg? 37. Given that the relative molecular mass (RMM) of sodium chloride is 58.5 g/mol, what amounts of sodium chloride powder would be required to prepare 300 mL of a solution containing 50 mmol/L? 38. A tablet labelled to contain 350 mg active ingredient has acceptable limits of 90– 110% of that amount. What are the corresponding figures in milligrams to the stated percentage range ? 39. How much of the amount of sodium ions does 50 mL sodium chloride solution 0.9% w/v intravenous infusion contain if there are 150 mmol each of Na+ and Cl–/L of NaCl 0.9% w/v IV infusion. 40. The amount of sodium chloride required to make 500 mL of a 0.1 mol/L solution (relative atomic mass [RAM]: sodium = 23; chlorine = 35.5.) 41. The amount of lymeycline contained in five Tetralysal 300 tablets. Each tablet contains 408 mg lymecycline equivalent to 300 mg tetracycline. 42. What is the number of moles of 5-aminolevulinic acid hydrochloride in 50 mL of a 1 mol/L solution?
  • 116. Reference: 1. Dosage Calculations: A Ratio-Proportion Approach, Gloria D. Pickar, EdD, RN 2007, 2nd Edition 2. Pharmaceutical and Clinical Calculations, Mansoor A.Khan. and Indra K. Reddy, 2000, 2nd Ed.